MEDVi's small-team story leaves the care-delivery work outside the headline
Evaluate the work behind a telehealth brand, distinguish projections from verified results and read the FDA letter at its actual scope.

A telehealth company can have a small internal team while relying on a much larger care-delivery system. Counting employees on the brand's payroll tells you little about the clinicians and pharmacies needed to fulfil a patient's order.
That is the missing denominator in the MEDVi growth story. Before treating it as proof of a nearly autonomous company, inspect which work sits outside the reported team and who remains responsible when that work fails.
Separate a revenue claim from an operating record
A projection describes expected future sales. It differs from recognised revenue for a completed period. Profit also depends on which costs the figure includes and the accounting used.
When a private-company story supplies striking numbers without audited statements, preserve that status. A reported founder claim can be discussed as a claim; it should not become a verified benchmark for what two employees can produce.
Headcount needs the same care. Ask whether it includes contractors. Ask which clinical functions are provided through external organisations. A count that excludes those participants is a measure of the internal organisation, not the entire system doing the work.
AI can help build a website or process an incoming message. Those uses do not demonstrate that a model has assumed clinical responsibility. Keep the claimed automation attached to the actual task it performs.
The warning letter names a concrete representation problem
The FDA's February 20, 2026 warning letter to MEDVi, LLC dba MEDVi identifies a Delaware address and website content reviewed in December 2025.
The agency said the pictured labelling suggested MEDVi compounded the drugs when it did not. It also objected to claims concerning compounded semaglutide and tirzepatide that it considered misleading about evaluation or approval.
That is a dated regulatory statement about the identified entity and content. It does not establish that every similarly named company is involved. Nor does the letter alone establish the final outcome of the company's response.
The operating lesson is specific: a brand must be able to explain who produced the medicine it presents. A simple purchasing interface can conceal that distinction from a patient unless the information is supplied accurately.
Outsourcing moves work beyond the payroll boundary
A telehealth workflow may involve separate organisations handling clinical assessment and dispensing. The patient still experiences the journey as one service.
A late shipment or an unclear instruction therefore needs an owner who can follow the handoff. "Our partner handles it" describes a division of work. It does not tell the patient how the problem will be resolved.
Map those handoffs before making a productivity claim. Identify which organisation verifies the prescription and which can answer a question about the dispensed product. Record where the platform can observe completion and where it depends on a partner's report.
This is an operational test of the business story. If the internal team is small because specialised work is purchased from elsewhere, assess the quality and cost of that arrangement. Otherwise a low employee count becomes a distracting proxy for efficiency.
The FDA's March 2026 announcement of telehealth warning letters shows that marketing representations were a wider enforcement focus. It does not establish that all companies used identical operating models.
A smooth intake does not establish product equivalence
The FDA's information on unapproved GLP-1 drugs explains that compounded products are not FDA-approved and describes concerns including dosing and shipping conditions.
That distinction should remain visible in any account of the service. Sharing an ingredient name does not establish that a compounded product has undergone the approval process applied to a named approved medicine.
Avoid turning a business analysis into treatment advice. A patient's options depend on clinical circumstances and the applicable rules. A founder's revenue claim supplies no evidence about which product is appropriate for that patient.
For the same reason, conversion rate is an incomplete quality measure. The service needs evidence about what happens after the form is submitted, including whether the intended care and follow-up occur.
The useful question for an AI-assisted healthcare business is where automation reduces administrative work while preserving accountable care. Start with one patient journey and name the organisation responsible at each handoff. That map will explain more about the business than a payroll headline.